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(h)SNCA gene silencing using a short hairpin (sh)RNA in rat substantia nigra (SN) protects
against a hSNCA-induced forelimb deﬁcit, but not dopamine (DA) neuron loss. Further-
more, the shRNA increases cell death in vitro, but the same target sequence embedded in a
microRNA30 transcript (mir30-hSNCA) does not. Objective: Examine hSNCA gene silencing
using mir30-hSNCA in vivo. Methods: Rats were stereotaxically injected into one SN with
adeno-associated virus serotype 2/8 (AAV)-hSNCA, AAV-hSNCA plus AAV-mir30-SNCA or
AAV-hSNCA plus a control non-silencing mir30-embedded siRNA and DA neuron markers
and associated behavior were examined. Results: AAV2/8-mediated SN hSNCA expression
induces a forelimb deﬁcit and tyrosine hydroxylase-immunoreactive (TH-IR) neuron loss.
hSNCA gene silencing using mir30-hSNCA protects against this forelimb deﬁcit at 2 m and
ameliorates TH-IR neuron loss. Striatal (ST) TH-IR ﬁber density and DA markers, assessed
by western blot, are unaffected by AAV-hSNCA alone. Co-expression of either silencing
vector reduces ST TH-IR ﬁbers, panTH in SN and Ser40 phosphorylated TH in SN and ST,
but does not affect vesicular monoamine transporter-2. However, hSNCA gene silencing
promotes partial TH-IR ﬁber recovery by 2 m. Co-expression of either silencing vector also
induces SN inﬂammation, although some recovery was observed by 2 m in hSNCA-silenced
SN. Conclusion: hSNCA gene silencing with AAV-mir30-hSNCA has positive effects on
forelimb behavior and SN DA neurons, which are compromised by inﬂammation and
reduced TH expression, suggesting that AAV2/8-mir30-hSNCA-mediated gene silencing,
although promising in vitro, is not a candidate for therapeutic translation for PD.
& 2014 The Authors. Published by Elsevier B.V. Open access under CC BY license.Elsevier B.V.
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Aberrant expression of alpha-synuclein (SNCA) occurs in a
number of diseases termed synucleinopathies, including Par-
kinson’s disease (PD), multiple system atrophy and dementia
with Lewy bodies (Marti et al., 2003). In familial forms of PD,
SNCA is directly associated with disease pathogenesis due to
three missense mutations in the SNCA gene or multiplication
of the gene (Lee and Trojanowski, 2006). SNCA is further
implicated in the pathogenesis of sporadic PD because it is a
major protein component of intra-cytoplasmic inclusions
termed Lewy bodies, a diagnostic hallmark of PD (Spillantini
et al., 1997). These ﬁndings suggest that therapeutically target-
ing aberrant SNCA expression may ameliorate disease patho-
genesis in both sporadic and familial PD.
Many SNCA-based experimental models of PD have been
created in an effort to better understand the role of SNCA in
disease pathogenesis. Transgenic mouse models of PD in
which SNCA is expressed under the control of various
promoters allowing expression in a ubiquitous or cell-
speciﬁc manner have been created. These mice vary in that
some do not display symptoms and others display varying
degrees of motor behavioral deﬁcits and/or dopamine (DA)
neuron degeneration in the substantia nigra (SN), which also
is a hallmark of PD pathogenesis (Chesselet, 2008). Rat
models of PD in which human (h) SNCA is experimentally
expressed in the SN using viral vectors also have been
created. In these rats, loss of DA neurons occurs over a short
time frame offering advantages for therapeutic studies (Kirik
et al., 2002, 2003; Lo Bianco et al., 2002). A rat model of PD in
which hSNCA is delivered to the rat SN using an adeno-
associated viral vector (AAV), similar to the one originally
characterized by Kirik’s group (Kirik et al., 2002), was used in
the current study.
RNA interference (RNAi) is an evolutionarily conserved
process of gene regulation involving double-stranded RNA
mediated degradation or translational inhibition of homo-
logous mRNAs (Fire et al., 1998; Scherr and Eder, 2007). This
RNAi process can be utilized as a therapeutic approach to
reduce expression of genes associated with disease. Several
different approaches have been taken to reduce aberrant
SNCA expression in rodent models of PD, including use of
ribozymes (Hayashita-Kinoh et al., 2006), intracellularly-
expressed single chain antibodies (Yuan and Sierks, 2009),
small inhibitory RNAs (Lewis et al., 2008; McCormack et al.,
2010), short hairpin (sh) RNAs (Sapru et al., 2006), microRNAs
(mir) (Han et al., 2011) and most recently, mirtrons (Sibley
et al., 2012) that target SNCA. In the current study, a mir-
embedded siRNA was used to reduce aberrant expression of
hSNCA in a rat model of PD.
We previously observed that expression of an shRNA
speciﬁc for hSNCA protects against a forelimb motor deﬁcit
induced by ectopic expression of hSNCA in rat SN. However,
an accompanying loss of DA neurons in the SN was also
observed (Khodr et al., 2011). Toxicity due to expression of an
shRNA has been observed in other studies in various cell
types, including neurons (Boudreau et al., 2008, 2009;
Castanotto et al., 2007; Grimm et al., 2006; McBride et al.,
2008; Yi et al., 2005). In vitro, this hSNCA-speciﬁc shRNA alsoreduces survival of DA PC12 cells. However, toxicity of this
shRNA in PC12 cells is eliminated by embedding the silencing
sequence in a mir30 transcript (Han et al., 2011). This ﬁnding
is in line with the ﬁndings of McBride et al. who showed safer
silencing when an initially toxic shRNA sequence is
embedded in a mir30 backbone (McBride et al., 2008). To
further develop our SNCA gene silencing approach for PD,
here we report in vivo results testing the less toxic mir30-
embedded hSNCA-speciﬁc silencing vector (mir30-SNCA) in
rat SN.2. Results
2.1. Optimizing AAV-hSNCA to AAV-mir30-SNCA ratio
An initial dose study was performed to determine the optimal
ratio of AAV2/8-hSNCA to AAV2/8-mir30-SNCA, to verify expres-
sion of hSNCA in the rat SN and identify a dose of AAV2/8-
hSNCA that reproduces the deﬁcit in ipsilateral forelimb use
previously reported for AAV2/2-hSNCA (Khodr et al., 2011). Three
AAV-hSNCA doses and six AAV-mir30-SNCA vector doses were
injected unilaterally into the SN together or separately (Table S1),
and the rats were assessed for levels of hSNCA expression,
TH-immunoreactive (IR) cell counts at one level of SN and
forelimb paw use at 1 month.
After injection of AAV-hSNCA, a dose dependent level of
expression of hSNCA-IR was observed in soma and ﬁbers in
ipsilateral SN and ventral tegmental area (VTA) and in ﬁbers
in ipsilateral striatum (ST) (Fig. 1a). A dose dependent
signiﬁcant loss of TH-IR neurons in these rats was also
observed (Table S1). Reduced contralateral forelimb use was
observed at the lowest dose (0.61010 vg) of AAV-hSNCA
(Fig. 1b).
When different ratios of mir30-SNCA were examined,
hSNCA-IR was found to be reduced in rats that received the
lowest dose of mir30-SNCA (1:3 ratio), although hSNCA
expression was still detectable in cell bodies in the SN and
in ﬁbers in both SN and ST. At the highest dose of mir30-
SNCA (1:55 ratio), hSNCA-IR was not detected in ST and only
rare hSNCA-IR cells or ﬁbers were detected in the SN,
although a diffuse background of hSNCA-IR was observed in
the SN (Fig. 1a). A statistically signiﬁcant protection from the
AAV-hSNCA-induced deﬁcit in contralateral forelimb use was
observed at a hSNCA to mir30-SNCA ratio of 1:55, but not at a
ratio of 1:29 or 1:3 in this pilot study with n¼3 (contra:
F5,12¼3.8, p¼0.0275; ipsi: F5,12¼6.2, p¼0.0046; Fig. 1b). How-
ever, no signiﬁcant differences in numbers of TH-IR neurons
between control and injected SN at any ratio of AAV-hSNCA
to AAV-mir30-SNCA were found (Table S1). Because TH
neuron counts do not differ between injected and control
SN at any ratio of hSNCA to mir30-SNCA (Table S1), the
optimal ratio was determined by the efﬁciency of hSNCA-IR
silencing and the protection against the deﬁcit in forelimb
motor behavior, which differs among hSNCA to mir30-SNCA
ratios. Based on the results of this pilot study, the subsequent
efﬁcacy experiments were carried out using the 1:55 hSNCA
to mir30-SNCA ratio.
Fig. 1 – Efﬁciency of hSNCA gene silencing at different doses of AAV2/8-hSNCA and AAV2/8-mir30-hSNCA. Different doses of AAV2/
8-hSNCA and ratios of AAV2/8-hSNCA to AAV2/8-mir30-hSNCA were injected into SN of rats to determine optimal doses and ratios
to use for efﬁcacy experiments. All doses and ratios tested are shown in Table S1. (a) Representative images showing expression of
hSNCA at 1 month are shown for both the SN and ST of rats that were injected with the low dose (0.61010 vg, upper panel) or high
dose (2.51010 vg, lower panel) of AAV8-hSNCA alone (left panels) or with AAV2/8-mir30-hSNCA (right panels) at a ratio of 1:3 (lower
panels) or 1:55 (upper panels). At the 1:3 ratio, hSNCA expression in both neurons and ﬁbers in SN and in ﬁbers in ST is visibly
reduced compared to the respective hSNCA alone group, but is still apparent. At the 1:55 ratio, hSNCA expression is barely detectable
in either SN or ST. Images were taken at the same settings. Size bar: 50lm. Additional images that include hSNCA-IR for the 1:29
ratio of AAV8-hSNCA to AAV8-mir30-hSNCA are shown in Fig. S1. (b) Forelimb preference was tested using the cylinder test at 1
month after injection. Ipsilateral and contralateral forelimb use are shown from rats injected with the low dose of AAV2/8-hSNCA
alone or with three different doses of silencing vector with (a ratio of 1:3, 1:29 or 1:55) or without AAV2/8-hSNCA (a ratio of 0:29 or
0:55). The number of times each paw was used on the ﬁrst 25 rearings was counted and is expressed as a percentage of total paw
use (mean7SEM). Statistical differences compared to rats injectedwith hSNCA alone are as follows: npr0.05; nnpr0.01. hSNCA gene
silencing signiﬁcantly ameliorates the forelimb deﬁcit observed in hSNCA-treated rats at the 1:55 hSNCA to silencing vector ratio.
The 1:55 hSNCA to silencing vector ratio was chosen for the efﬁcacy studies because hSNCA-IR is severely reduced and forelimb
behavior is signiﬁcantly ameliorated.
b r a i n r e s e a r c h 1 5 5 0 ( 2 0 1 4 ) 4 7 – 6 0 492.2. hSNCA gene silencing in SN and ST
To conﬁrm that rats in each treatment group were transduced
with the vectors to the same extent, DNA levels of hSNCA andturbo GFP (representing either mir30-SNCA or a control, non-
silencing, silencing vector containing a scrambled target
sequence (NS)) were determined by quantitative real time QPCR
at 10d (Fig. S2a and b) and 2 months (Fig. 2a) survival in the
b r a i n r e s e a r c h 1 5 5 0 ( 2 0 1 4 ) 4 7 – 6 050ventral midbrain. All groups received similar levels of hSNCA
vector DNA (Fig. S2b and Fig. 2a). Groups injected with AAV-
hSNCA and AAV-mir30-SNCA, or AAV-hSNCA and AAV-NS,
received similar levels of silencing vector DNA, as measured by
turbo GFP (Fig. S2a). hSNCA DNA also was detected in the ST of
rats that received AAV-hSNCA alone, but not in ST from other
treatment groups (Fig. S3).
hSNCA expression levels were examined at the mRNA
level in the ventral midbrain and ST at 10d (Fig. S2c) and 2
months (Fig. 2b and c) using qRT-PCR to conﬁrm hSNCA
expression and silencing. hSNCA mRNA levels are signiﬁ-
cantly reduced in rats injected with AAV-hSNCA and AAV-
mir30-SNCA compared to rats injected with AAV-hSNCA
alone at both the level of the ventral midbrain (pr0.05;
F5,24¼20.77, po0.0001; Fig. 2b) and the ST (pr0.001;
F5,24¼285.5, po0.0001; Fig. 2c). hSNCA mRNA levels also are
reduced in ST injected with AAV-hSNCA and AAV-mir30-
SNCA compared to those injected with AAV-hSNCA and AAV-
NS (pr0.001, F5,24¼285.5, po0.0001; Fig. 2c). However, hSNCA
RNA levels in ventral midbrain injected with AAV-hSNCA and
AAV-mir30-SNCA do not differ from those in ventral mid-
brain injected with AAV-hSNCA and AAV-NS. These data
suggest that hSNCA mRNA and vector DNA, in the case of
injection of AAV-hSNCA alone, are transported to the ST.2.3. hSNCA gene silencing protects against a hSNCA-
induced deﬁcit in forelimb motor behavior
To examine effects of hSNCA expression and silencing in the
SN on motor behavior, forelimb behavior was examined using
the cylinder test 1 and 2 months after unilateral SN injection
of AAV-hSNCA, AAV-hSNCA and AAV-mir30-SNCA or AAV-
hSNCA and AAV-NS (Fig. 3). As expected, a preference for
ipsilateral forelimb use and a deﬁcit in contralateral forelimb
use was observed in rats expressing hSNCA (i.e., rats injected
with AAV-hSNCA alone or AAV-hSNCA and AAV-NS) at both
1 month (hSNCA: pr0.01, ipsi-77.974.2%, contra-21.173.9%,Fig. 2 – hSNCA gene silencing in the ventral midbrain and ST. hS
in rats unilaterally injected with AAV2/8-hSNCA or AAV2/8-hSN
non-silencing control vector (NS). Non-injected (control SN) and v
dissected from rats and processed for qPCR and/or qRT-PCR. (a)
midbrain and, and (c) hSNCA mRNA in the ST. DNA and mRNA
Asterisks represent statistical differences between control and i
nnnpr0.001). Note that hSNCAmRNA levels are signiﬁcantly redu
speciﬁc mir30-hSNCA silencing vector. In contrast, the levels of
treatment groups and neither the hSNCA-speciﬁc nor the NS siln¼16; hSNCA and NS: pr0.01, ipsi-69.373.1%, contra-26.47
2.0%, n¼15; F4,132¼11.78, po0.0001) and 2 months (hSNCA:
pr0.05, ipsi-77.576.2%, contra-22.576.2%, n¼11; hSNCA
and NS: pr0.05, ipsi-80.073.1%, contra-18.873.3%, n¼10;
F4,87¼18.69, po0.0001) after injection. hSNCA gene silencing
with mir30-SNCA results in protection against the hSNCA-
induced deﬁcit in forelimb use by 2 months after injection,
when ipsilateral and contralateral forelimb use does not
statistically differ (ipsi-51.172.1%, contra-45.371.1%, n¼11),
although a preference (pr0.05) for ipsilateral forelimb use
(57.373.1%,n¼16) and a deﬁcit in contralateral forelimb use
(37.372.8%) was observed at 1 month in rats where hSNCA
was silenced with mir30-SNCA. The 2-way ANOVA showed
no signiﬁcant effect of time or interaction of time and
treatment.2.4. Effect of hSNCA gene silencing on TH-IR neuron
numbers
SN brain sections from rats injected with AAV-hSNCA, AAV-
hSNCA and AAV-mir30-SNCA or AAV-hSNCA and AAV-NS at
1 and 2 months survivals were stained for TH-IR. Qualita-
tively, SNs injected with AAV-hSNCA and AAV-NS have the
most evident reduction in TH-IR, where TH-IR neurons were
observed in smaller, narrower bands, at both survivals
(Fig. S4a and Fig. 4a), compared with the other treatments.
TH-IR neurons throughout the entire SN were counted using
unbiased stereology at both 1 and 2 months (Fig. S4b and
Fig. 4b). At 1 month, TH-IR neurons are reduced in hSNCA-
expressing SN, (hSNCA: 85217538, pr0.01, n¼5, and hSNCA
and NS: 75577642, pr0.001, n¼5) compared to the respective
control SN (hSNCA: 12,1167290, n¼5, and hSNCAþNS: 12,415
7377, n¼5), but are not signiﬁcantly different in SN where
hSNCA is silenced using mir30-SNCA (10,11871290, n¼5)
compared to control SN (12,6797251, n¼5; F5,24¼10.72,
po0.0001), suggesting protection of DA neurons by silencing
of hSNCA. However, TH-IR cell counts are not statisticallyNCA expression at the DNA and RNA levels was determined
CA with either the AAV2/8-mir30-SNCA silencing vector or a
ector injected ventral midbrain and corresponding STs were
hSNCA DNA in ventral midbrain, (b) hSNCA mRNA in ventral
levels relative to β-actin mRNA are shown (mean7SEM).
njected SN unless otherwise noted (npr0.05; nnpr0.01;
ced in both ventral midbrain and ST in rats injected with the
hSNCA vector DNA remain high in injected midbrain of all
encing vectors signiﬁcantly affect these levels.
Fig. 3 – hSNCA gene silencing protects against a hSNCA-
induced deﬁcit in forelimb motor behavior. Rats were
injected with AAV8-hSNCA alone or AAV8-hSNCA plus
either AAV8-mir30-hSNCA or a non-silencing control vector
(NS) into one SN. Forelimb preference was tested using the
cylinder test at both 1 and 2 months after injection. The
number of times each paw was used on the ﬁrst 25 rearings
was counted and is expressed as a percentage of total paw
use (mean7SEM). Statistical differences are shown for each
treatment group as follows: differences compared to
ipsilateral forelimb use (npr0.05; nnpr0.01; nnnpr0.001),
and differences compared to contralateral forelimb use
(†pr0.05; ††pr0.01). At 1 month, all treatment groups show
a preference for contralateral paw use apparently due to
expression of hSNCA in the SN, although this deﬁcit is less
signiﬁcant in the hSNCA silenced group. However, by 2
months, rats in which hSNCA is silenced recover and show
no preference in paw use.
b r a i n r e s e a r c h 1 5 5 0 ( 2 0 1 4 ) 4 7 – 6 0 51different in injected SNs of all treatment groups. At 2 months,
TH-IR neuron numbers also are reduced (pr0.001) in hSNCA-
expressing SN (i.e. hSNCA: 85187586, n¼6, and hSNCA and
NS: 64667264, n¼5) compared to respective control SN
(hSNCA: 12,1457204, n¼6, and hSNCA and NS: 12,2547262,
n¼5). SNCA gene silencing ameliorates this deﬁcit in TH-IR
neurons because rats where hSNCA was silenced with mir30-
SNCA have a less severe reduction (pr0.05) in the number of
TH-IR neurons in the injected SN (10,3557732, n¼6) com-
pared to the respective control SN (12,6337213), and this
reduction is not signiﬁcant in comparison to the control SNsfrom the hSNCA-expressing groups. Injection of AAV-hSNCA
and AAV-NS exacerbates the deﬁcit in TH-IR neurons in that
SNs injected with AAV-hSNCA and AAV-NS have reduced TH-
IR neurons compared to SNs injected with AAV-hSNCA and
AAV-mir30-SNCA, as well as those injected with AAV-hSNCA
alone (pr0.05 compared to hSNCA, pr0.001 compared to
hSNCA and mir30-SNCA; F5,28¼28.90, po0.0001). Note that
although signiﬁcant differences were observed between trea-
ted SNs at 2 months, and not at 1 month, the pattern and
magnitude of effects at 1 and 2 months are very similar and
do not differ signiﬁcantly between time points, which was
veriﬁed by a lack of signiﬁcant effect of time or interaction of
time and treatment by 2-way ANOVA.
2.5. Expression of either mir30-SNCA or NS silencing
vector results in loss of total TH expression, without loss of
VMAT2 in ventral midbrain
To further examine effects of hSNCA expression and silen-
cing on DA neurons in the SN, the ventral midbrain was
dissected from rats injected with AAV-hSNCA, or AAV-
hSNCA and either AAV-mir30-SNCA or AAV-NS silencing
vector and endogenous rat DA phenotypic markers were
examined at the mRNA and protein levels (Fig. 5). TH mRNA
levels (Fig. 5a) are reduced in ventral midbrain injected with
either AAV-mir30-SNCA or AAV-NS silencing vector com-
pared to AAV-hSNCA-injected or control ventral midbrain,
and this reduction is greatest in ventral midbrain injected
with AAV-hSNCA and AAV-NS, which have reduced TH
mRNA levels compared to all control ventral midbrains
(F5,24¼15.66, po0.0001). Protein levels follow this same trend
in that ventral midbrain injected with either AAV-mir30-
SNCA or AAV-NS silencing vector exhibit reduced TH protein
using a pan TH antibody (F5,24¼6.148, p¼0.0008; Fig. 5c), as
well as Ser40 phosphorylated (P-Ser40) TH antibody (Fig. 5d),
an activated form of TH, compared to AAV-hSNCA-injected
and control ventral midbrain. However, control ventral mid-
brains from rats that received either silencing vector also
show reduced P-Ser40 TH protein expression (F5,24¼8.421,
p¼0.0007). Interestingly, protein levels of vesicular monoa-
mine transporter 2 (VMAT2, Fig. 5e) are not signiﬁcantly
affected by treatment, suggesting that expression of TH is
selectively affected by silencing vector in DA neurons.
2.6. Expression of either mir30-SNCA or NS silencing
vector results in an initial loss of TH-IR ﬁbers in the ST, which
partially recovers after 2 months of hSNCA gene silencing
ST brain sections from rats injected with AAV-hSNCA, AAV-
hSNCA and AAV-mir30-SNCA or AAV-hSNCA and AAV-NS at
1 and 2 months survivals were stained for TH-IR. Qualita-
tively, ST co-injected with AAV-hSNCA and either AAV-
mir30-SNCA or AAV-NS silencing vector have the most
evident reductions in TH-IR at 1 month (Fig. 6a). By 2 months,
TH-IR in ST injected with AAV-hSNCA and AAV-mir30-
hSNCA exhibits recovery compared to the 1 month time
point (Fig. 6b). The density of TH-IR ﬁbers at the level of the
anterior commissure was measured using NIH Image J at
both 1 and 2 months (Fig. 6c and d). TH-IR ﬁber density
measurements are not signiﬁcantly affected by hSNCA
Fig. 4 – hSNCA gene silencing ameliorates loss of TH-IR neurons in rat SN. (a) Representative staining for TH-IR in non-
injected, control SN and SN of each treatment group and (b) the number of TH-IR neurons in the entire SN at 2 months using
unbiased stereology. Cell counts (Mean7SEM) are shown for control and injected SN in each treatment group. Asterisks
represent statistical differences between control and injected SN unless otherwise noted (npr0.05; nnnpr0.001). All SNs
injected with AAV8-hSNCA exhibit reduced TH-IR counts compared to control SNs. SNCA gene silencing ameliorates this
deﬁcit in TH-IR neurons (the difference between injected and control SN is reduced), although this deﬁcit is still present.
Co-injection of AAV8-NS exacerbates the deﬁcit in TH-IR neurons in that TH-IR counts in injected SN are signiﬁcantly reduced
when compared to those in hSNCA-injected or hSNCA silenced SN. Size bar: 100 lm.
b r a i n r e s e a r c h 1 5 5 0 ( 2 0 1 4 ) 4 7 – 6 052expression at either time point. However, TH-IR ﬁber density is
reduced in ST of rats co-injected with AAV-hSNCA and either
AAV-mir30-SNCA or AAV-NS silencing vector compared to ratsinjected with AAV-hSNCA (1 month-pr0.05; F2,12¼5.731, p¼
0.0179, 2 month-hSNCA and NS: pr0.001, hSNCA and mir30-
SNCA: pr0.05; F2,14¼24.27, po0.0001). Partial recovery from the
Fig. 5 – Expression of TH, but not VMAT2, is reduced when the silencing construct is co-expressed with hSNCA in the ventral
midbrain. The left and right ventral midbrains were dissected from rats 2 months after injection with AAV8-hSNCA, or AAV8-
hSNCA with either the AAV8-hSNCA silencing or non-silencing vector (NS). DA phenotypic markers were examined at both
the mRNA (a) and protein (b–e) levels. Levels of TH mRNA relative to β-actin mRNA are shown in (a) as ΔΔCt (mean7SEM).
A representative western blot is shown in (b) and relative levels of TH (c), P-Ser40 TH (d) and VMAT2 (e) protein (compared to
alpha-tubulin) are graphed as percent (mean7SEM). Asterisks represent statistical differences between control and injected
unless otherwise noted (npr0.05; nnpr0.01; nnnpr0.001). Note that at this dose of AAV-hSNCA, there is little overall loss of TH
protein or mRNA. However, expression of TH, but not VMAT2, is signiﬁcantly reduced in rats that received AAV8-hSNCA with
either AAV8-silencing vector compared to that in the group that received AAV8-hSNCA alone.
b r a i n r e s e a r c h 1 5 5 0 ( 2 0 1 4 ) 4 7 – 6 0 53initial reduction in TH ﬁbers (at 1 month) is observed by 2
months after injection in rats in which hSNCA was silenced
with mir30-SNCA; ST injected with AAV-hSNCA and AAV-
mir30-SNCA have increased ﬁber density measurements com-
pared to ST injected with AAV-hSNCA and AAV-NS (pr0.01),
and TH ﬁber density measurements in ST injected with AAV-
hSNCA and AAV-mir30-SNCA at 2 months are greater than
those at 1 month (pr0.05). However, 2-way ANOVA did not
show a signiﬁcant effect of time, but did show a trend regarding
an interaction of time and treatment (F2,26¼2.847, p¼0.0762).
These data suggest that although expression of silencing vector
is toxic to TH-IR ﬁbers, SNCA gene silencing promotes recovery
from this initial toxic effect.
2.7. Expression of either mir30-SNCA or NS silencing
vector results in loss of total P-Ser40 TH expression, without
loss of VMAT2 in the ST
To further examine effects of hSNCA expression and silencing
on DA ﬁbers in the ST, the left and right ST were dissected from
rats injected with AAV-hSNCA, or AAV-hSNCA and either AAV-
mir30-SNCA or AAV-NS silencing vector, and DA phenotypic
markers were examined at the protein level (Fig. 7). Although all
injected ST trend toward reduced levels of TH protein asdetected by either the pan TH (Fig. 7b) or Ser40 phosphorylated
TH (Fig. 7c) antibodies compared to control ST, these trends are
only signiﬁcant in ST injected with AAV-hSNCA and AAV-NS
for pan TH (pr0.05; F5,24¼4.333, p¼0.006) and in ST injected
with AAV-hSNCA and either AAV-mir30-SNCA or AAV-NS silen-
cing vector for P-Ser40 TH (pr0.01; F5,24¼8.893, po0.0001).
Similar to the observations in the ventral midbrain, protein
levels of VMAT2 (Fig. 7d) are not affected by treatment, suggest-
ing that DA ﬁbers in the ST are equivalent in all groups although
TH expression is affected by expression of either mir30-SNCA or
NS silencing vector.
2.8. Co-expression of either mir30-SNCA or NS silencing
vector increases inﬂammation in the SN
To examine the effect of hSNCA expression and silencing on
inﬂammation, SN sections were stained for Iba-1-IR, which is
up-regulated during microglia activation, at both 1 and 2
months (Fig. 8). Qualitatively, a small increase in Iba-1-IR
compared to control SN was observed in SN injected with
AAV-hSNCA alone. However, a strong inﬂammatory response
in SN, as detected by increased Iba-1-IR was observed in rats
injected with either AAV-mir30-SNCA or AAV-NS silencing
vector. This increase in Iba-1-IR was the greatest after 1
Fig. 6 – TH-IR ﬁbers in ST exhibit recovery by 2 months when hSNCA is silenced. Representative sections showing TH-IR in
control ST and ST from rats injected with AAV8-hSNCA alone or AAV8-hSNCA with either silencing vector at 1 (a) or 2 months
(b). Density of TH-IR ﬁbers was determined using NIH Image J™ and is graphed as a percent of injected/control (mean7SEM) at
1month (c) and 2 months (d). Statistical differences are compared to AAV8-hSNCA unless otherwise noted (npr0.05;
nnpr0.01; nnnpr0.001). Note that there is little loss of TH-IR ﬁbers in ST at this dose of AAV-hSNCA. In contrast, inclusion of
either silencing vector leads to a signiﬁcant loss of TH-IR ﬁbers in ST at 1 month. By 2 months, ﬁber loss has recovered
signiﬁcantly in rats with silenced hSNCA (2 months, 75.875.4 vs. 1 month, 49.879.2, pr0.05), but TH-IR ﬁbers do not show
recovery in rats that received the non-silencing vector. Size bar, 400 lm.
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Fig. 7 – Total P-Ser40 TH expression, but not total VMAT2, is reduced in ST injected with either silencing vector. The left and
right ST were dissected from rats 2 months after injection of AAV8-hSNCA, or AAV8-hSNCA with either AAV8-silencing
vector. DA phenotypic markers were examined at the protein level. A representative western blot is shown in (a) and relative
levels of TH (b), P-Ser40 TH (c) and VMAT2 (d) protein expression (compared to alpha-tubulin) are graphed (mean7SEM).
Statistical differences are noted between control and injected ST (npr0.05; nnpr0.01).
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SNCA. By 2 months, a partial recovery was observed in SN
where hSNCA is silenced with mir30-SNCA, although Iba-1-IR
remains increased compared to control SN. In contrast, the
increased Iba-1-IR observed in SN injected with AAV-hSNCA
and AAV-NS remains consistent from 1 to 2 months.3. Discussion
The aberrant expression of SNCA observed in several diseases
termed synucleinopathies, which includes PD, suggests that
targeting SNCA for downregulation is a plausible therapeutic
approach. We have been investigating whether hSNCA RNAi
can protect DA neurons against hSNCA-induced toxicity and
functional deﬁcits in a rat model where hSNCA is ectopically
expressed in the SN. In the current study, delivery of hSNCA
to the rat SN using AAV2/8 induced a deﬁcit in forelimbmotor
behavior and loss of TH-IR neurons in the SN at 1 month.
A mir30-embedded shRNA silencing vector (mir30-SNCA)
silenced ectopic hSNCA expression, in vivo, in rat SN and
ST, which resulted in both positive and negative effects on
the nigrostriatal DA system and associated behavior. Positive
effects of hSNCA gene silencing included protection against
the hSNCA-induced deﬁcit in forelimb motor behavior by 2
months, amelioration of TH-IR cell loss in the SN, partial
recovery from initial mir30-SNCA-induced toxicity on TH-IR
ﬁbers in the ST and partial recovery from initial mir30-SNCA-
induced inﬂammation in the SN. However, the negative
effects of this hSNCA gene silencing included the incomplete
protection of TH-IR neurons in the SN, an initial toxic effecton TH-IR ﬁbers in the ST and the presence of inﬂammation in
the SN, as well as reduced total TH expression in the SN and
reduced total Ser40 phosphorylated TH in the ST (as mea-
sured by western blot). These negative hSNCA gene silencing
effects suggest that this hSNCA-speciﬁc mir30-embedded
shRNA (mir30-SNCA), at the currently examined dose, does
not hold potential for development as a clinical therapy.
Apparent inconsistencies between TH expression data in
the ventral midbrain as assessed by western blot and TH-IR
neuron counts in the SN were observed. These inconsisten-
cies were present in rats that received AAV-mir30-hSNCA
with AAV-hSNCA, which show partial protection of TH-IR
neuron numbers compared to rats that received AAV-hSNCA
alone, but reduced total TH protein, and in rats that received
hSNCA alone, which show loss of TH-IR neurons but no effect
on total TH expression. These TH inconsistencies are likely
explained by differences in production of TH at the cellular
level. For example, the protected TH-IR neurons found in the
hSNCA-silenced SNs (hSNCA and mir30-SNCA) may express
low TH levels per neuron, leading to reduced total TH in the
ventral midbrain. On the other hand, compensation for lost
TH-IR neurons by increased TH expression in surviving
neurons could explain the lack of an effect on total ventral
midbrain TH expression observed in rats that received AAV-
hSNCA alone.
Two different hSNCA-expressing control groups were used
in this study, one that received AAV-hSNCA alone and one
that received AAV-hSNCA and a control, non-silencing, silen-
cing vector containing a scrambled sequence (AAV-NS),
which interestingly differed in some of the toxic effects
examined. Both hSNCA-expressing groups exhibited a similar
Fig. 8 – Co-expression of silencing vector with AAV8-hSNCA induces an inﬂammatory response in the SN. Brain sections
stained for Iba-1 as a marker for microglia are shown in control SN (left panels) and in AAV8-hSNCA-, AAV8-hSNCAþAAV8-
mir30-SNCA- and AAV8-hSNCAþAAV8-NS-injected SN at 1month (middle panels) and 2 months (right panels). Note that Iba-
1-IR is very high in SN of rats injected with either silencing vector and that although this is somewhat reduced by 2 months, it
remains higher than in rats injected with AAV-hSNCA alone. Size bar: 100 lm.
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the SN by 1 month. However, rats that received AAV-hSNCA
and AAV-NS exhibited greater toxic effects than those
observed in rats that received AAV-hSNCA alone, which
included loss of TH-IR ﬁbers in the ST, reduction in total TH
expression in the ventral midbrain and the ST, as measured
by western blot, and an increased inﬂammatory response as
detected by Iba-1-IR. The greater toxicity observed in rats
treated with AAV-hSNCA and AAV-NS could be attributed to
silencing vector design, off-target effects of the scrambled
sequence, or to increased viral load. It is also possible that co-
injection of silencing vector resulted in some unknown
modulatory effect on hSNCA vector expression. Rats that
received hSNCA alone did exhibit some reduction in total TH
expression in the ventral midbrain and ST, as measured bywestern blot, although this reduction was not signiﬁcant.
A lack of toxicity on TH-IR ﬁbers in the ST by AAV2/8-hSNCA
alone, has also been observed in some studies where hSNCA
was delivered to the SN using either AAV2/6 (Azeredo da
Silveira et al., 2009) or AAV2/8 (McFarland et al., 2009).
However, other studies using AAV2/2, 2/5 or 2/6 have shown
hSNCA-induced reductions in TH-IR ﬁbers in the ST by 8
weeks (Decressac et al., 2012; Gorbatyuk et al., 2008; Kirik
et al., 2002; Lundblad et al., 2012). These differences most
likely reﬂect varying levels of hSNCA protein in DA axons due
to differences in vector dose, serotype and/or efﬁciency of
retrograde transport, but may also result from toxic effects at
different ST levels since only one ST level was quantiﬁed. The
AAV-hSNCA and AAV-NS group is the most appropriate
hSNCA-expressing control group for assessment of effects
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these groups received similar viral load and were injected with
similar vector constructs. When compared to the AAV-hSNCA
and AAV-NS group, hSNCA gene silencing with mir30-SNCA
results in signiﬁcant protective effects on forelimb motor
behavior, TH-IR neurons in the SN and TH-IR ﬁbers in the ST.
However, toxic effects that may have resulted from high viral
load or from silencing vector design were observed in both the
NS and mir30-SNCA groups. These negative effects include
reductions in total TH in the ventral midbrain and in P-Ser40
TH in the ST, as well as the presence of inﬂammation in the SN,
even though an apparent qualitative recovery from inﬂamma-
tion was observed after hSNCA gene silencing with mir30-SNCA
(1 month survival vs. 2 month survival).
As discussed, silencing of hSNCA using mir30-SNCA ame-
liorated some toxic effects observed in hSNCA-expressing
rats. Of these positive hSNCA gene silencing effects, the
protection against the hSNCA-induced forelimb deﬁcit is of
particular interest because it appears to be due speciﬁcally to
silencing hSNCA in DA terminals in the ST. At 2 months after
injection, expression of hSNCA in the ST correlated with the
deﬁcit in contralateral forelimb use. Possible correlation of
these measures was not assessed at 1 month because the
survival time for all rats in this portion of the study was 2
months. hSNCA mRNA may have been silenced either at the
terminals or in the cell body, thereby reducing transport of
hSNCA mRNA to the ST. Our data suggest that the presence
of hSNCA with either silencing vector induces loss of TH
ﬁbers in the ST. Importantly, hSNCA gene silencing promotes
a partial recovery from this initial toxic effect on TH-IR ﬁbers
in the ST, which is not observed in the AAV-NS control group.
This partial protection of TH-IR ﬁbers in rats where hSNCA
was silenced also correlates with the recovery in forelimb
behavior between 1 and 2 months in this group. These
ﬁndings are in agreement with our previous study in which
a hSNCA-speciﬁc shRNA was used to silence hSNCA. In that
study, not only was there a protection of forelimb use, but
data from ﬂuorogold tract tracing suggested that hSNCA gene
silencing promoted sprouting of new nigrostriatal ﬁbers from
surviving nigral DA neurons (Khodr et al., 2011). Sprouting
may also have occurred in the current study, although we
cannot rule out the possibility that partial recovery in TH
protein in ST also contributed to behavioral improvement.
Although hSNCA gene silencing with mir30-SNCA exhib-
ited positive effects, the observed negative effects exclude the
current dose of mir30-SNCA from further preclinical devel-
opment. The negative effects may have been due to expres-
sion of the silencing construct or to viral dose. Toxicity on
midbrain DA neurons due to high viral loads or high trans-
gene expression also has been observed by others. Ulusoy
et al. (2009) observed that high titer AAV5 vectors expressing
either an shRNA or GFP induced loss of DA neurons, as well
as microglial activation, and Koprich et al. (2010, 2011)
observed that high titer AAV1/2 expressing GFP induced loss
of SN neurons. However, in the current study, differences
were observed between rats injected with AAV-hSNCA and
AAV-mir30-hSNCA and rats injected with AAV-hSNCA and
AAV-NS even though both groups received similar doses of
vectors. Moreover, effects were signiﬁcantly better in rats in
which hSNCA was silenced compared to NS control rats.It is possible that a lower ratio of mir30-SNCA to hSNCA
could reduce some of the observed negative effects either due
to reduced silencing vector expression or reduction of viral load.
Further preclinical testing of different vector ratios and the
effects of silencing vector alone might lead to identifying a
viable path to the clinic for SNCA gene silencing. A conundrum
with attempting to resolve the problem of viral load is that
reducing delivery of hSNCA may result in a lack of hSNCA-
induced toxicity and reducing delivery of silencing vector may
not silence hSNCA enough to produce protective effects. Our
current data suggest that a lower dose of this mir30-hSNCA
would result in incomplete gene silencing and reduced beha-
vioral protection at 1 month. However, long-term dose studies
may reveal greater behavioral protective effects by lower doses
of silencing vector. For example, protection of forelimb motor
behavior at the 1:55 dose examined in the current experiments
did not occur until 2 months when both ipsilateral and
contralateral paws were used to similar extents (Fig. 3), even
though ipsilateral and contralateral forelimb use was signiﬁ-
cantly different from respective hSNCA-induced forelimb use at
1 month (Fig. 1). Another approach to reduce possible toxicity
due to high viral load might be to express mir30-SNCA under a
stronger or cell-speciﬁc promoter. Alternatively, AAV-mir30-
SNCA could be tested in other models where hSNCA and
silencing vector expression are uncoupled in order to prevent
possible undesired modulatory effects of silencing vector virus
on delivery or expression of AAV-hSNCA, such as transgenic
hSNCA mouse models that present with behavioral and mid-
brain DA neuron deﬁcits (Masliah et al., 2000; Richﬁeld et al.,
2002). However, symptoms in these transgenic models do not
become evident until 12 months, a serious drawback compared
to the rapid degeneration model used in the current study.
The ﬁndings presented in this paper reveal positive and
negative effects of hSNCA silencing vector expression in the
rat SN and suggest that gene silencing using this AAV2/8-
mir30-hSNCA construct, although promising in vitro, is not a
candidate for therapeutic translation for PD at the currently
tested dose. However, the observed partial protective effects
of this silencing vector on DA neurons and motor function
suggest that further modiﬁcation of vector design may
provide a more promising silencing vector outcome, perhaps
by expressing the silencing sequence under a stronger pro-
moter so that a lower viral load can be used and/or by
designing silencing sequences that minimize potential and
undesirable off target effects.4. Experimental procedures
4.1. Generation of adeno-associated viral (AAV) shuttle
plasmids and virus packaging
Shuttle plasmids pAAV-CBA-hSNCA, pAAV-mir30-non-
silencing (NS) and pAAV-mir30-SNCA were cloned as pre-
viously described (Han et al., 2011; Khodr et al., 2011).
Expression cassettes were conﬁrmed by sequencing and
vectors were packaged as serotype AAV2/8 by the University
of Pennsylvania Vector Core. Viral titers were: AAV-CBA-
hSNCA – 6.221013 vector genomes (vg)/ml, AAV-mir30-NS
– 1.851014 vg/ml, AAV-mir30-SNCA – 1.761014 vg/ml.
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Adult male Sprague Dawley rats weighing 175–200 g were
purchased from Harlan laboratories (Indianapolis, IN) and
housed in the Children’s Hospital of Chicago Research Center
animal facility on a 12 h light/dark cycle with food and water
available ad libitum. Animal care and use procedures were
conducted in accordance with NIH, USDA and institutional
guidelines.
4.3. Treatment groups and sample sizes
An initial vector dose response study was carried out with a 1
month survival using 48 rats to determine the optimal
dilution of AAV2/8-hSNCA and ratio of AAV2/8-hSNCA to
silencing vector for use in efﬁcacy experiments (Table S1). For
the behavioral study, treatment groups were: AAV- hSNCA
alone (n¼16 at 1 month; n¼11 at 2 months); AAV-hSNCA and
AAV-NS (n¼15 at 1 month and 10 at 2 months); AAV-hSNCA
and AAV-mir30-SNCA (n¼16 at 1 month and n¼11 at 2
months). At 1 month, rats were sacriﬁced for histological
analysis of TH-IR ﬁber density in ST and Iba-1 in SN (n¼5).
The remaining rats were sacriﬁced at 2 month with half the
rats prepared for histology and half for molecular analyses
(n¼5–6). A separate group of rats was injected for molecular
analysis at 10 days (n¼3).
4.4. Stereotaxic surgery and post-operative animal care
The skin overlying the skull of isoﬂurane-anesthetized rats
was shaved. Stereotaxic surgeries were carried out using a
Stoelting stereotaxic apparatus equipped with a Stoelting
quintessential stereotaxic injector holding a 10 ml Hamilton
syringe with a 26 gauge needle. A hole was drilled in the skull
over the appropriate injection site at stereotaxic coordinates,
5.5 mm posterior, 1.9 mm lateral and 7.4 mm ventral from
Bregma (SN injection). The syringe was inserted into the brain
at a speed of 1 mm/min and then allowed to remain in
place for 2 min before vector injection. 2 μl of each virus
mixture was injected at a rate of 0.5 μl/min into one SN, and
the needle was left in place for 5 min at the end of the
injection in order to minimize diffusion up the needle track.
The doses of each vector used for the dose response experi-
ments are shown in Table S1. For the efﬁcacy experiment,
rats received 6.22109 vg of AAV2/8-hSNCA alone or with
either 3.511011 vg of AAV2/8-mir30-NS or 3.261011 vg of
AAV2/8-mir30-SNCA in a 2 μl volume. The syringe was with-
drawn at a rate of 1 mm/min. The drill hole was plugged
with gel foam to control bleeding and Marcaine was spread
around the surgical site. The skin was sutured and treated
with topical antibiotic ointment and rats were returned to the
vivarium upon recovery from anesthesia. Twenty-four hours
after surgery, rats were transferred to a clean cage and the old
bedding was autoclaved.
4.5. Non-drug induced forelimb motor behavior
Rats were placed inside of a plexiglass cylinder, partially
surrounded by mirrors in a quiet, dark room. The activity of
each rat was recorded on videotape under red light for a10min period. The number of times each pawwas used for wall
touches on the ﬁrst 25 rearings of each rat was counted by an
observer blinded to treatment group to determine forelimb use
preference as previously published (Schallert et al., 2000). All
treated rats underwent forelimb behavior testing at 1 month or
at both 1 and 2 months after vector injection.
4.6. Tissue preparation
For molecular analyses, rats were anesthetized with sodium
pentobarbital (75 mg/kg) and perfused through the ascending
aorta with 0.9% saline. The left and right ventral mesence-
phalons, as well as the left and right striata were collected
and stored at 80 1C until homogenization. To extract nucleic
acids and the soluble protein fractions, tissues were homo-
genized in homogenization buffer (1 PBS, 1% Triton-Tx,
5 mM EDTA) containing 10 μl/ml of HALT protease and phos-
phatase inhibitor (Thermo Scientiﬁc) using a glass homoge-
nizer. After 4 freeze-thaw cycles in an ethanol bath at 80 1C
for 2 min and a 37 1C water bath for 2 min, homogenates were
centrifuged at 100,000 g for 1hr at 4 1C. The supernatant was
collected and the pellet (ribosomal mRNA, DNA, insoluble
protein) was suspended in TRI Reagent™ (Ambion, Austin, TX).
The TRI protocol was used to extract RNA and DNA.
For histology, sodium pentobarbital-anesthetized rats
were perfused through the ascending aorta with 0.9% saline
containing 0.002% sodium nitrite, followed by 4% phosphate
buffered paraformaldehyde (pH¼7.4). Brains were post-ﬁxed
overnight in 5% sucrose–4% paraformaldehyde and then
cryoprotected in an increasing gradient of sucrose concentra-
tions (10–30%) in 0.1 M PBS. A sliding microtome (Leica
SM2000 R) was used to cut sections in the coronal plane at
40 μm. Six serial sets of sections were collected and stored in
cryoprotectant solution at 20 1C.
4.7. QPCR
TRI-extracted RNAwas treated with a DNase before quantitation.
RNA and DNA levels were measured using quantitative Taq-
Man™ or SYBR Green real-time PCR on an Applied Biosystems
(Foster City, CA) 7500 fast real-time PCR system. TaqMan RNA
reactions contained 25 ng of RNA, 12.5 μl of 2 TaqMan Uni-
versal PCR buffer, 6.25 U of MuLV reverse transcriptase, 1.25 U of
RNase inhibitor, 0.25 μl of each primer (10 μM forward β-actin, TH,
or 20 μM forward hSNCA and 20 μM reverse β-actin, hSNCA or
10 μM reverse TH), and 0.5 μl of probe (5 μM) in a 25 μl volume.
TaqMan DNA reactions contained the same components as the
RNA reactions, except water replaced the reverse transcriptase
and RNase inhibitor. For DNA, only hSNCA plasmid content was
measured using TaqMan real-time PCR. SYBR Green real-time
PCR was used to measure turbo GFP plasmid (i.e. silencing
vector) content. SYBR Green reactions contained 25 ng of DNA,
12.5 μl of 2 Power SYBR Green Master Mix, 0.25 μl of AmpErase
and 2.25 μl of each primer (10 μM) in a 25 μl volume. Target-
speciﬁc primers and probes were designed using Primer Express
3.0 (Applied Biosystems) and BLAST (blast.ncbi.nlm.nih.gov).
Primers and probes used are as follows: hSNCA (fwd primer:
GACCAGTTGGGCAAGAATGAAG, rev primer: GGTTCGTAGTCTT-
GATACCCTTCCT, probe: TCTGGAAGATATGCCTGTGGATCCT-
GACA); rat TH (fwd primer: CGGAAGAGATTGCTACCTGGAA,
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GAAGGGCCTCTATGCTACC; rat β-actin (fwd primer: TCACCC-
CTGTGCCCATCTATG, rev primer: CATCGGAACCGCTCATTGCC
GATAG, probe: ACGCGCTCCCTCATGCCATCCTGCGT); and turbo
GFP (fwd primer: AGCGTGATCTTCACCGACAAG, rev primer:
CTGCCATCCAGATCGTTATCG). Probes contained a FAM reporter
dye and a QSY7 quencher dye, except for the hSNCA probe,
which contained a BHQ1 quencher dye. Reactions were incu-
bated at 48 1C for 30min, 95 1C for 10min, then 40 cycles of 95 1C
for 15 s and 59 1C for 1min. Data are expressed as delta Ct
compared to β-actin Ct and compared to the control SN in the
group of rats treated with hSNCA.
4.8. Western blots
Protein levels in the soluble fraction were measured using the
Bio-Rad DC protein assay kit (500-0111). Samples containing
25 μg of total protein were separated by SDS-PAGE on 4–15% Tris
HCl gels and transferred to PVDF membranes (Millipore) at 12 V
for 1 h. Membranes were blocked with 5% blocking reagent for
1 h at room temperature, then incubated in primary antibody
overnight at 4 1C (1:2000 rabbit anti-P Ser40 TH; 1.25 μg/ml rabbit
anti-VMAT2, Millipore, Billerica, MA) or for 1hr at room tempera-
ture (1:2500 rabbit anti-pan TH, Millipore; 1:10,000 mouse anti-α-
tubulin, Sigma). After washes, membranes were incubated for
1hr at room temperature in horseradish peroxidase (HRP)-con-
jugated goat anti-mouse or goat anti-rabbit secondary antibody
(1:5000, Santa Cruz, CA). Membranes were developed using
Supersignal West Pico Luminol/enhanced solution and West
Pico stable peroxide solution (Pierce, Appleton, WI), and exposed
to Kodak BioMax Light Film. Films were scanned as 600 dpi
grayscale tiff images using a CanoScan8400F ﬂatbed scanner,
and net intensities of bands weremeasured using CarestreamMI
SE software.
4.9. Immunohistochemistry
Free-ﬂoating tissue sections were rinsed of cryoprotectant solu-
tion. For diaminobenzidine (DAB) staining, tissue sections were
incubated in H2O2 in order to quench endogenous peroxidase
activity. Sections were blocked in normal goat serum (NGS) for
1hr to minimize nonspeciﬁc antibody binding and then incu-
bated overnight at room temperature in primary antibody (for
ﬂuorescence: 1:50 mouse anti-hSNCA, Invitrogen; for DAB: 1:2000
rabbit anti-pan TH, or 1.5 μg/ml rabbit anti-Iba-1, Wako). After
rinses, sections were incubated in an appropriate secondary
antibody (1:100 Cy3-conjugated goat anti-mouse; 1:200 Cy2-
conjugated goat anti-rabbit, Jackson Immunoresearch, West
Grove, PA; or, 1:500 biotinylated goat anti-rabbit IgG, Vector
Laboratories) for 2.5 h at room temperature. For ﬂuorescence
staining, sections were mounted on slides, air dried overnight,
and coverslipped with Fluorosave (Calbiochem, La Jolla, CA).
For DAB staining, sections were rinsed and incubated with
avidin-biotinylated enzyme complexes (Vector Laboratories) for
2 h at room temperature and developed using a DAB solution
(50mM sodium acetate, 10mM imidazol, 0.4mg/ml DAB, 0.005%
H2O2) containing or not containing 0.5 g/ml nickel sulfate. Sec-
tions were mounted on slides, dried overnight, dehydrated and
coverslipped. Slides were evaluated using a Leica DMR upright
microscope equipped for epiﬂuorescence microscopy.4.10. DA marker ﬁber measurements in ST
ST sections were stained for TH immunoreactivity (IR) using
nickel enhancement and slides were scanned as 600 dpi, 8 bit
grayscale tiff images using a CanoScan8400F ﬂatbed scanner
with automatic settings disabled. One section at the level of
the anterior commissure (0.26 mm from Bregma) was cho-
sen from each brain for ﬁber density measurement. Using Fiji
software (http://imageJ.nih.gov/ij), each ST was outlined
using the freehand tool, processed to correct for background
and brightness, converted to a binary image and the number
of pixels in the ST determined as a measure of TH-IR ﬁber
density. ST ﬁber density data are expressed as a percentage of
injected vs control ST for each treatment group.
4.11. TH cell counts
Sections of SN were stained for TH-IR without nickel enhance-
ment. For the dose response study, the number of TH-IR
neurons was counted in both injected and control SNs in one
section from each brain at the level of the medial terminal
nucleus accessory optic tract (5.3 mm from Bregma) using
Neurolucida software (Micro Bright Field Biosciences).
For the efﬁcacy study, unbiased stereology was used to
determine the total number of TH-IR neurons in each SN.
Seven sections at similar anterior to posterior levels were
chosen throughout the anterior-posterior extent of the SN in
every brain. The number of TH-IR cells was counted in
injected and control SN using StereoInvestigator™ software
(Micro Bright Field Biosciences). Parameters were as follows:
grid size (8080), frame size (175175), guard zones (3 μm),
optical dissector height (10 μm). The Gundersen coefﬁcient of
error was r0.07 for TH neuronal counts in the control SN
and r0.11 for TH neuronal counts in experimental SN.
For both counting methods, only large TH-IR neurons
(greater than 15 μm in diameter) were counted to avoid
counting interneurons or dying neurons.
4.12. Imaging
Histology images were collected using a Retiga 4000R digital
camera on a Leica DMR upright microscope. Adobe Photoshop
CS5 was used to compile multi-photo plate ﬁgures.
4.13. Statistical analysis
Data were analyzed using Prism software. Kruskal–Wallis
one-way ANOVAs followed by Dunn’s post hoc tests were
used to compare treatment groups for forelimb behavior
analysis. All other data were analyzed using a parametric
one-way ANOVA followed by Tukey’s post hoc tests. Statis-
tically signiﬁcant differences were set at pr0.05. Data are
expressed as mean7SEM.Acknowledgments
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